Pensionfund Sabic Makes New $1.86 Million Investment in Pfizer Inc. $PFE

Pensionfund Sabic bought a new stake in shares of Pfizer Inc. (NYSE:PFE) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 74,800 shares of the biopharmaceutical company’s stock, valued at approximately $1,863,000.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Fiduciary Alliance LLC grew its stake in Pfizer by 46.4% during the 3rd quarter. Fiduciary Alliance LLC now owns 145,263 shares of the biopharmaceutical company’s stock worth $3,701,000 after purchasing an additional 46,043 shares in the last quarter. Y Intercept Hong Kong Ltd purchased a new position in shares of Pfizer in the 3rd quarter valued at about $3,019,000. Money Concepts Capital Corp grew its position in shares of Pfizer by 29.9% during the third quarter. Money Concepts Capital Corp now owns 248,251 shares of the biopharmaceutical company’s stock worth $6,325,000 after buying an additional 57,188 shares in the last quarter. Vista Investment Partners LLC grew its position in shares of Pfizer by 236.1% during the third quarter. Vista Investment Partners LLC now owns 69,613 shares of the biopharmaceutical company’s stock worth $1,774,000 after buying an additional 48,900 shares in the last quarter. Finally, Kepler Cheuvreux Suisse SA purchased a new stake in shares of Pfizer during the third quarter worth approximately $16,613,000. 68.36% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts recently weighed in on PFE shares. BMO Capital Markets reaffirmed an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a report on Monday, March 9th. Bank of America dropped their price objective on shares of Pfizer from $29.00 to $28.00 and set a “neutral” rating on the stock in a research report on Monday, December 15th. Weiss Ratings restated a “hold (c-)” rating on shares of Pfizer in a report on Thursday, January 22nd. Morgan Stanley set a $27.00 price objective on shares of Pfizer and gave the stock a “positive” rating in a research report on Tuesday, March 17th. Finally, UBS Group initiated coverage on shares of Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $28.19.

Trending Headlines about Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Analyst upgrade/price-target bump: Guggenheim raised its Pfizer price target to $36 and holds a Buy rating, backing upside tied to key pipeline readouts and boosting sentiment among growth/pipeline-focused investors. Guggenheim price target report
• Positive Sentiment: Pipeline upside — prostate cancer and oncology momentum: Several analysts highlight potential high-value outcomes from an ongoing prostate-cancer trial and broader oncology progress, suggesting binary upside that could re-rate the stock if positive. Analyst bullish case on prostate cancer trial
• Neutral Sentiment: Management investor access — Q1 webcast scheduled for May 5: Pfizer invited the public to view a May 5 analyst call tied to its First Quarter 2026 Performance Report; that scheduled update creates a clear near-term catalyst for guidance or pipeline commentary. May 5 webcast invitation
• Neutral Sentiment: Management highlights oncology milestones: CFO Dave Denton discussed recent oncology progress on NYSE Live, reinforcing management’s message that non-COVID franchises and oncology are growth pillars. This supports a constructive narrative but is not immediately revenue-producing. CFO oncology interview
• Negative Sentiment: Lyme vaccine trial—strong efficacy but missed primary endpoint: Pfizer and partner Valneva reported >70% efficacy, yet the trial missed its pre-specified primary endpoint because fewer cases occurred than expected. That creates regulatory and execution uncertainty; Valneva’s shares plunged, underscoring market concern about read-across risk. Pfizer will pursue regulatory filings, but approval risk and timing remain uncertain. Lyme vaccine efficacy and trial miss

Pfizer Stock Up 0.8%

Shares of NYSE:PFE opened at $26.98 on Wednesday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The stock has a market cap of $153.39 billion, a P/E ratio of 19.83 and a beta of 0.47. The firm has a fifty day moving average price of $26.75 and a 200 day moving average price of $25.64. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The firm had revenue of $17.56 billion for the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the previous year, the firm posted $0.63 EPS. The firm’s revenue for the quarter was down 1.2% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.